Intelligence Platform
Patents
Browse 1,641 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 6805858
Methods for the administration of adenovirus p53
expired patentUS 6800475
Isolation of a human retrovirus
expired patentUS 6794188
Retrovirus vectors derived from avian sarcoma leukosis viruses permitting transfer of gene
expired patentUS 6794174
Full-length infectious cDNA clones of tick borne flavivirus
expired patentUS 6790841
2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents
expired patentUS 6787333
Retrovirus isolated from humans
expired patentUS 6787573
Antiviral therapy
expired patentUS 6780847
Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, v
expired patentUS 6777179
Method for selective inactivation of viral replication
expired patentUS 6770283
DNA expression systems based on alphaviruses
expired patentUS 6752987
Adenovirus encoding human adenylylcyclase (AC) VI
expired patentUS 6750043
Viral vectors having reduced virulence
expired patentUS 6743577
Methods of using cyanovirins to inhibit viral infection
expired patentUS 6740320
Recombinant P53 adenovirus methods and compositions
expired patentUS 6719978
Virus-like particles for the induction of autoantibodies
expired patentUS 6713066
Production of attenuated respiratory syncytial virus vaccines involving modification of M2
expired patentUS 6713078
Retrocyclins: antiviral and antimicrobial peptides
expired patentUS 6705556
Composition and method for inducing tolerance to viral infection in aquatic animals
expired patentUS 6703232
Method of producing infectious reovirus
expired patentUS 6699481
Peptides for inhibition of herpes simplex virus entry
expired patentUS 6696562
Avian astrovirus
expired patentUS 6692750
Alphavirus expression vector
expired patentUS 6689877
Methods and compositions for the treatment of human immunodeficiency virus infection
expired patentUS 6689362
Method for treating T-lineage leukemias and lymphomas using a CD7-specific monoclonal anti
expired